PARP inhibitors such as olaparib have transformed treatment for prostate cancer, but the drugs will eventually stop working and cancers will continue to grow A ‘liquid biopsy’ blood test can pick up ...

Olaparib monotherapy may be a treatment option for some patients with high-risk biochemically recurrent prostate cancer, according to researchers.

AstraZeneca Pharma India Limited has received permission to import for sale and distribution in Form CT-20 from the CDSCO, ...

Scientists have worked out a way of predicting how long a prostate cancer patient will continue to respond to the PARP ...

The phase II trial found that over 80 per cent of men with prostate cancer whose tumours had mutations in the BRCA genes responded well to treatment with the targeted drug olaparib. Men in the study ...

New Delhi: The Drug Controller General of India (DCGI), Rajeev Raghuvanshi, has directed state authorities to withdraw AstraZeneca’s Olaparib Tablets, 100mg and 150mg, due to potential adverse ...

Up to 600 women with a hereditary type of the disease could benefit each year. Health bosses said olaparib had the potential to make "a huge impact", giving a better chance of survival.

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Some 800 people in total will be eligible for the treatment. Around 500 men with advanced ...

Get detailed information on Olaparib, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

The drug olaparib is designed to treat specific cancers linked to faulty versions of genes known as BRCAs. Around 500 men with advanced prostate cancer and 300 women with HER2-negative early ...